19th Nov 2007 17:00
AstraZeneca PLC19 November 2007 Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R We hereby inform you that on 16 November 2007, Simon Lowth, a Director ofAstraZeneca PLC, was granted awards under the terms of the AstraZeneca ShareOption Plan and the AstraZeneca Performance Share Plan over the Company'sUSD0.25 Ordinary Shares. Details of the awards are as follows: AstraZeneca Share Option Plan Number of shares over which option is Exercise price per Period when Total number ofName of Director granted share exercisable shares under option S Lowth 18,665 2210p 16.11.10-15.11.17 18,665 The option will become exercisable on16 November 2010 subject to the achievementof certain performance conditions. The conditions, which will not be subject toany retesting, are that the earnings per share of the Company must increase bythe increase in the UK Retail Prices Index plus 5% per annum on average overthree years, and that no significant unforeseen event has taken place which, inthe reasonable opinion of the Remuneration Committee, has resulted in majorreputational damage to AstraZeneca, and the circumstances of which areexceptional enough to justify the option not vesting and becoming exercisable.Failure to satisfy either or both of these conditions will result in the lapseof the option in its entirety. AstraZeneca Performance Share Plan Target number of Total interest shares awarded in shares after Name of Award price per this award Percentage ofDirector share Normal vesting date shares in issue S Lowth 15,554 2210p 16 November 2010 16,404 0.001% The AstraZeneca Performance Share Plan was approved by shareholders at theCompany's AGM in 2005. Awards made under the Plan may not generally vest beforethe third anniversary of the relevant date of grant nor unless the specifiedperformance target(s) have been met at the end of the three year period which,for this award, is 1 January 2007 to 31 December 2009. The performance target that applies to this award is the Company's TotalShareholder Return ("TSR") compared to the TSR of a selected peer group of 12other pharmaceutical companies. The actual number of shares to which aparticipant may become unconditionally entitled will depend on the extent towhich the performance target(s) have been met. A summary of the Plan, includinga more detailed explanation of the performance target(s), can be found in theAstraZeneca Annual Report and Form 20-F Information 2006 which is available onthe Company's website www.astrazeneca.com. G H R Musker Company Secretary 19 November 2007 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca